Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.56 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652798 | 0.86 | SIGMAR1 (0.47) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1514871 | 0.85 | SIGMAR1 (0.50) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL688048 | 0.83 | SIGMAR1 (0.48) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1936134 | 0.80 | SIGMAR1 (0.50) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL11564682 | 0.77 | SIGMAR1 (0.63) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL297545 | 0.76 | SIGMAR1 (0.45) | SIGMAR1MC4RLMNAPOLBCYP3A4 | |
| SCHEMBL276364 | 0.76 | SIGMAR1 (0.56) | SIGMAR1MC4RDRD4ALDH1A1 | |
| SCHEMBL2316823 | 0.76 | MC4R (0.56) | SIGMAR1MC4RLMNAPOLBACHE | |
| SCHEMBL1044027 | 0.73 | SIGMAR1 (0.52) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL2321298 | 0.73 | MC4R (0.49) | SIGMAR1MC4RLMNAPOLBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | claimed |
| CN-103221047-B | Compounds and methods | TEMPERO PHARMACEUTICALS INC | 2014-12-17 | — | — | CN | claimed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | claimed |
| CN-103221047-A | Compounds and methods | TEMPERO PHARMACEUTICALS INC | 2013-07-24 | — | — | CN | claimed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | claimed |
| WO-2013009830-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| WO-2013009810-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | claimed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | claimed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| CN-103221047-B | Compounds and methods | TEMPERO PHARMACEUTICALS INC | 2014-12-17 | — | — | CN | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| CN-103221047-A | Compounds and methods | TEMPERO PHARMACEUTICALS INC | 2013-07-24 | — | — | CN | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013009830-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013009810-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013006408-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | SIGMAR1 804/4885MC4R 2342/4885DRD4 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.